Baidu
map

Geno Biol:新方法有助找到与癌症相关的病原体

2019-10-28 张家伟 新华社

英国东英吉利大学近日表示,该校研究人员领衔的团队发明了一种病原体检测新方法,可更有效找到那些与癌症相关的病原体,未来有望开发出更好的癌症诊治方法甚至相关疫苗。

英国东英吉利大学近日表示,该校研究人员领衔的团队发明了一种病原体检测新方法,可更有效找到那些与癌症相关的病原体,未来有望开发出更好的癌症诊治方法甚至相关疫苗。

此前的研究显示,一些癌症与传染性病原体相关,例如幽门螺杆菌和人乳头瘤病毒分别与癌和宫颈癌相关。

该研究团队对目前基因组序列数据中细菌和病毒检测的计算方法进行了基准化分析,并综合最好的计算模块,发明了一种名为SEPATH的病原体检测方法。研究人员利用这一方法对真实的肿瘤样本进行检测,除了已知的相关病原体外,又发现了一些新的病原体。

报告作者之一、该校的丹·布鲁尔博士说,当对肿瘤样本进行全基因组测序时,其中存在的病原体DNA(脱氧核糖核酸)也会被测序,这使得研究人员能够检测并量化这些病原体,帮助研究人员找到病原体与不同癌症之间的联系。

相关结果刊登在最新一期英国《基因组生物学》杂志上。

原始出处:

Abraham Gihawi, Ghanasyam Rallapalli, Rachel Hurst, et.al. SEPATH: benchmarking the search for pathogens in human tissue whole genome sequence data leads to template pipelines. Genome Biology 22 October 2019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953176, encodeId=080619531e65a, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 23 09:34:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767707, encodeId=91fe1e67707bc, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 20 08:34:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918887, encodeId=be22191888e86, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 23 05:34:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903385, encodeId=06b719033854b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Jul 06 00:34:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375190, encodeId=d5ca3e51904f, content=你好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5VZmGPhlj42jydETWiaZvXnCw66qZDIztRGYvbzlF4HGl5jja5QPUjiasKJyRl8r8TibJdc11l5bQ61PDibFbV90wa/0, createdBy=6e242014098, createdName=谷君-梅斯医学, createdTime=Fri Nov 15 10:55:30 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510655, encodeId=6b6e15106556e, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Wed Oct 30 03:34:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953176, encodeId=080619531e65a, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 23 09:34:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767707, encodeId=91fe1e67707bc, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 20 08:34:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918887, encodeId=be22191888e86, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 23 05:34:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903385, encodeId=06b719033854b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Jul 06 00:34:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375190, encodeId=d5ca3e51904f, content=你好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5VZmGPhlj42jydETWiaZvXnCw66qZDIztRGYvbzlF4HGl5jja5QPUjiasKJyRl8r8TibJdc11l5bQ61PDibFbV90wa/0, createdBy=6e242014098, createdName=谷君-梅斯医学, createdTime=Fri Nov 15 10:55:30 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510655, encodeId=6b6e15106556e, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Wed Oct 30 03:34:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953176, encodeId=080619531e65a, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 23 09:34:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767707, encodeId=91fe1e67707bc, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 20 08:34:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918887, encodeId=be22191888e86, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 23 05:34:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903385, encodeId=06b719033854b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Jul 06 00:34:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375190, encodeId=d5ca3e51904f, content=你好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5VZmGPhlj42jydETWiaZvXnCw66qZDIztRGYvbzlF4HGl5jja5QPUjiasKJyRl8r8TibJdc11l5bQ61PDibFbV90wa/0, createdBy=6e242014098, createdName=谷君-梅斯医学, createdTime=Fri Nov 15 10:55:30 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510655, encodeId=6b6e15106556e, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Wed Oct 30 03:34:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
    2020-05-23 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953176, encodeId=080619531e65a, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 23 09:34:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767707, encodeId=91fe1e67707bc, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 20 08:34:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918887, encodeId=be22191888e86, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 23 05:34:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903385, encodeId=06b719033854b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Jul 06 00:34:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375190, encodeId=d5ca3e51904f, content=你好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5VZmGPhlj42jydETWiaZvXnCw66qZDIztRGYvbzlF4HGl5jja5QPUjiasKJyRl8r8TibJdc11l5bQ61PDibFbV90wa/0, createdBy=6e242014098, createdName=谷君-梅斯医学, createdTime=Fri Nov 15 10:55:30 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510655, encodeId=6b6e15106556e, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Wed Oct 30 03:34:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1953176, encodeId=080619531e65a, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 23 09:34:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767707, encodeId=91fe1e67707bc, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 20 08:34:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918887, encodeId=be22191888e86, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 23 05:34:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903385, encodeId=06b719033854b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Jul 06 00:34:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375190, encodeId=d5ca3e51904f, content=你好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5VZmGPhlj42jydETWiaZvXnCw66qZDIztRGYvbzlF4HGl5jja5QPUjiasKJyRl8r8TibJdc11l5bQ61PDibFbV90wa/0, createdBy=6e242014098, createdName=谷君-梅斯医学, createdTime=Fri Nov 15 10:55:30 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510655, encodeId=6b6e15106556e, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Wed Oct 30 03:34:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
    2019-11-15 谷君-梅斯医学

    你好!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1953176, encodeId=080619531e65a, content=<a href='/topic/show?id=d441e1440e8' target=_blank style='color:#2F92EE;'>#癌症相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71440, encryptionId=d441e1440e8, topicName=癌症相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 23 09:34:00 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767707, encodeId=91fe1e67707bc, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Mar 20 08:34:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918887, encodeId=be22191888e86, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat May 23 05:34:00 CST 2020, time=2020-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903385, encodeId=06b719033854b, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Jul 06 00:34:00 CST 2020, time=2020-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375190, encodeId=d5ca3e51904f, content=你好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5VZmGPhlj42jydETWiaZvXnCw66qZDIztRGYvbzlF4HGl5jja5QPUjiasKJyRl8r8TibJdc11l5bQ61PDibFbV90wa/0, createdBy=6e242014098, createdName=谷君-梅斯医学, createdTime=Fri Nov 15 10:55:30 CST 2019, time=2019-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510655, encodeId=6b6e15106556e, content=<a href='/topic/show?id=2efbe0807b1' target=_blank style='color:#2F92EE;'>#病原体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70807, encryptionId=2efbe0807b1, topicName=病原体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6c210226313, createdName=xue8605, createdTime=Wed Oct 30 03:34:00 CST 2019, time=2019-10-30, status=1, ipAttribution=)]
    2019-10-30 xue8605

相关资讯

Nature:重磅!科学家在人类癌症基因组非编码区域中鉴别出关键的致癌突变

近日,一项刊登在国际杂志Nature上的研究报告中,来自加拿大安大略省癌症研究所的科学家们通过研究在人类癌症基因组中的大量非编码区域(也被称之为人类癌症DNA的“暗物质”)中发现了一种新型的致癌突变;这种突变或能作为一种新型潜在的治疗靶点,帮助科学家们开发治疗多种类型癌症的新型疗法,包括脑癌、肝癌和血液癌症等。

精简管线!阿斯利康放弃与和黄医药合作开发Savolitinib肾癌3期研究

阿斯利康放弃与和黄医药合作开发savolitinib(沃利替尼) 作为乳头状肾细胞癌(PRCC)单一疗法的后期临床试验。这项临床3期研究是阿斯利康从今年第二季度开始精简研发管线策略中的五个项目之一。

癌症早筛 人生棋局的“胜负手”

“人生如同在下一盘棋,每一个人都有自己人生棋局。癌症早筛就像棋局一样,如果开局的好,及早发现和治疗癌症,一辈子都会健健康康。”在谈到自己患结直肠癌的经历时,中国围棋协会副主席聂卫平如是感慨地说。

2019年度ESMO肿瘤大会热点解析

ESMO(European Society for Medical Oncology)举办的欧洲肿瘤内科学会(ESMO Congress)是欧洲乃至全球最专业,也是最着名的肿瘤学大会之一,它承载着医学界最先进的技术和最权威的学术交流。

Nature:正常结直肠上皮细胞中体细胞突变的情况

已有的研究显示,大肠腺瘤序列提供了一个范式框架,可以用于理解随后的体细胞遗传变化和随之而来的导致癌症的克隆扩增。

Nat Immunol:耶鲁科学家开发全新的癌症免疫疗法

免疫疗法已经彻底改变了癌症的治疗,但是现有的疗法并不适用于所有患者,而且对某些癌症根本不起作用。因为它有时无法识别癌细胞的所有分子伪装,因此大大降低了治疗效果。 北京时间10月15日,发表在《Nature Immunology》上的一项新研究中,美国耶鲁大学的研究团队开发的一种新系统可以让癌细胞无处遁形,以帮助免疫系统发现并消灭其他形式的免疫疗法无法识别的肿瘤。 为了解决现有疗法无法识别癌细胞

Baidu
map
Baidu
map
Baidu
map